NCT01391221

Inflammatory Markers and Cognitive Function in Major Depression

Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal · Academic / Other
• Sex: All
• Age: 20 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Major depression is accompanied by cognitive changes as well as alterations in multiple physical functions. The inflammatory system is altered generally toward a pro-inflammatory state. Antidepressants are associated with a decrease in this proinflammatory state. This study aims to generate pilot data concerning a possible link between cognition, inflammation and response to treatment. The cognitive function of subjects with major depression will be tested before and after treatment with duloxetine. Inflammatory markers will be measured at both time points.

Conditions

• Major Depression

Interventions

Type	Name	Description
DRUG	Duloxetine	Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention

Timeline

• Start date: 2011-07-01
• Primary completion: 2013-08-01
• Completion: 2013-08-01
• First posted: 2011-07-11
• Last updated: 2012-07-19

Locations

2 sites across 1 country: Canada